C4 Therapeutics (CCCC) Income towards Parent Company (2019 - 2026)

C4 Therapeutics' Income towards Parent Company history runs 8 years deep, the most recent figure standing at -$27.4 million for Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 4.27% year-over-year to -$27.4 million in Q1 2026; TTM through Mar 2026 was -$106.0 million, a 2.63% decrease from a year earlier, with the FY2025 full-year figure at -$105.0 million, changed 0.31% from the prior year.
• Income towards Parent Company eased to -$27.4 million in Q1 2026 per CCCC's latest filing, from -$20.4 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$17.7 million in Q2 2024 and bottomed at -$128.7 million in Q2 2022.
• The 5-year median for Income towards Parent Company is -$31.6 million (2022), against an average of -$35.3 million.
• Across the five-year window, Income towards Parent Company plunged 469.84% in 2022 and jumped 72.08% in 2023, its largest moves.
• Year by year, Income towards Parent Company stood at -$37.2 million in 2022, then increased by 6.53% to -$34.8 million in 2023, then increased by 0.53% to -$34.6 million in 2024, then soared by 41.1% to -$20.4 million in 2025, then slumped by 34.77% to -$27.4 million in 2026.
• Per Business Quant, the three latest CCCC Income towards Parent Company figures stand at -$27.4 million (Q1 2026), -$20.4 million (Q4 2025), and -$32.2 million (Q3 2025).